Pyc Therapeutics Ltd has released a press release.
Correction to Trading Halt Request
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Change of Managing Director
- ADOA Program - Presentation of Clinical Data at NOSA 2025
- PKD Program - Presentation of Safety Data at ANZSN
- Appendix 4E
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
Later from PYC Therapeutics
- Board and Management Changes
- ADOA Program Progressing to Multiple Dose Study
- PMS Program Data Supports Progression to Human Trials
- ADOA Program Initiation of Global Repeat Dose Study
- Sustained Vision Improvement in RP11 Patients
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics